ArticleOpen heart2026
Nationwide analysis of mortality and causes of death in heart failure: updated insights from the Thai Heart Failure Registry (THFR).
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) remains associated with high mortality worldwide despite advances in guideline-directed therapy.
aimTo characterise the patterns and causes of death among Thai patients with chronic HF enrolled in a nationwide registry and to identify predictors of mortality.
methodsWe performed a prospective cohort analysis of 2879 HF patients enrolled in the Thai Heart Failure Registry (THFR) which has enrolled patients since 2020. The present analysis included those enrolled between January 2021 and December 2023. Causes of death were ascertained via electronic health records and adjudicated as cardiovascular (CV), non-CV or undetermined. Mortality incidence rates were calculated per 100 person-years. Multivariable Cox proportional hazards models identified independent predictors of all-cause mortality.
resultsOver a median follow-up of 23 months, 301 patients (10.5%) died (incidence rate 6.8 per 100 person-years). Of these, 149 (49.5%) were CV deaths, 116 (38.5%) were non-CV deaths, 36 deaths (12.0%) were undetermined. In HF with reduced ejection fraction/HF with mildly reduced ejection fraction patients, CV deaths predominated compared with non-CV mortality (5.3% vs 3.9%), whereas HF with preserved ejection fraction patients experienced higher non-CV mortality compared with CV mortality (5.5% vs 4.1%), particularly sepsis. Independent predictors of mortality included ischaemic aetiology (HR 1.34; 95% CI 1.06 to 1.69), atrial fibrillation (HR 1.57; 1.24-2.00), peripheral oedema at presentation (HR 2.11; 1.57-2.85), hyponatraemia (serum Na<135 mmol/L; HR 1.83; 1.39-2.39), hypokalaemia (serum K<3.5 mmol/L; HR 1.44; 1.06-1.95), elevated blood urea nitrogen (>25 mg/dL; HR 1.56; 1.23-1.98) and prior loop diuretic use (HR 1.61; 1.21-2.14). Good guideline-directed medical therapy adherence is associated with a lower mortality despite the adjustment of confounders.
conclusionsAmong Thai HF patients, mortality remains high, with distinct patterns of CV versus non-CV deaths across left ventricular ejection fraction phenotypes. Targeted strategies addressing ischaemic heart disease, rhythm management, fluid status and electrolyte disturbances may reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.